Clinical Trial Update: Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating methylphenidate for attention and executive function deficits in children with sickle cell disease. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Cognitive Impairment
• Sickle Cell Disease

Drugs mentioned

• Methylphenidate (Methylphenidate)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Sickle Cell Disease, Executive Dysfunction | Phase 1 | Status: RECRUITING